BioSpace News Archive

Jan. 11, 2022 13:00 UTC – Strategic collaboration with Pfizer leverages Dren Bio’s proprietary platform to develop bispecific antibodies that connect tumor cells with myeloid cells resulting in immune stimulation, targeted phagocytosis and the cross-presentation of tumor neoantigens to potentially promote durable clinical responses – – Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potenti

Today Censis Technologies announces the retirement of CEO, Randy Smith. Randy joined Censis in February of 2005 and was promoted to CEO in 2006.

Nascent Biotech, Inc. is pleased to announce the completion of dosing of the second cohort of patients involved in the Company’s Phase I trial to evaluate Pritumumab as a treatment for Brain Cancer.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference taking place on January 10-13, 2022.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance.

PerkinElmer, Inc. today announced that it anticipates reported and organic revenue growth for the fourth quarter of 2021 of approximately -1% and -12%, respectively, versus the same period a year ago.

CanSino Biologics Inc. announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of CanSinoBIO’s Recombinant COVID-19 Vaccine for Inhalation Convidecia™as a heterologous booster.

Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label extension of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Progenity, Inc. today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of Gastroenterology, February 9-11, 2022.

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd (“InstaDeep”) today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2.